**Buprenorphine microinduction** (also referred to as low-dose buprenorphine induction or low-dose initiation) is an advanced clinical protocol where buprenorphine is gradually introduced in very small, incremental doses to transition a patient onto maintenance therapy 1-3.  
This method acts as a **"tapered cross-over"** to help patients with severe 7-hydroxymitragynine (7-OH) use disorder stabilize safely on medication-assisted treatment (MAT) 3\.

### Why Microinduction is Used for 7-OH Withdrawal

* **Bypasses the Comfort Barrier**: Traditional buprenorphine induction requires patients to wait until they are in moderate-to-severe active withdrawal before taking their first dose 1\. Microinduction allows patients to begin the transition immediately, **bypassing or dramatically minimizing the physical and psychological distress** of the acute waiting period 1, 2\.  
* **Prevents Precipitated Withdrawal**: Highly concentrated 7-OH is a potent mu-opioid receptor agonist 4\. Because buprenorphine is a partial agonist with an extremely high receptor affinity, introducing a standard dose of buprenorphine less than 24 hours after a patient's last 7-OH dose carries a **moderate-to-high risk of "precipitated withdrawal"** (suddenly displacing the 7-OH and triggering severe, acute withdrawal) 2, 4\. Microinduction slowly introduces buprenorphine onto the receptors to prevent this sudden shock 2, 3\.  
* **Improves Treatment Retention**: By mitigating severe autonomic distress and withdrawal spikes, microinduction makes the detox process far more tolerable, which helps keep patients engaged in treatment rather than leaving prematurely due to cravings or pain 2\.

### Clinical Case Evidence

The clinical feasibility of this approach for 7-OH is documented in a landmark case report presented at the **57th ASAM Annual Conference** 5:

* **The Patient**: A male in his 20s presented with severe 7-OH use disorder after consuming **30 mg to 50 mg of concentrated 7-OH daily for two years** 6, 7\.  
* **The Approach**: Because of the patient's exceptionally high daily intake and a history of severe withdrawal symptoms during previous quit attempts, clinicians determined that standard induction posed too high a risk for precipitated withdrawal 2, 7\. They initiated a **low-dose buprenorphine microinduction on Day 1** of his inpatient admission 8\.  
* **The Outcome**: The patient tolerated the microinduction smoothly with **minimal withdrawal symptoms** during the crossover 8\. He was successfully titrated to a total daily maintenance dose of **12 mg of buprenorphine** and safely discharged on Day 5 with his physical cravings and severe withdrawal symptoms fully stabilized 8\.

📋 I can compile a structured clinical reference sheet for you detailing the exact 7-OH withdrawal timeline, risk screening criteria, and buprenorphine dosing windows.